Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6242743 | 0.88 | FFAR1 (0.53) | SRD5A2EPHX2FFAR1ALDH1A1HPGD | |
| SCHEMBL8037910 | 0.88 | ALOX5 (0.61) | FFAR1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL31657190 | 0.85 | AKR1C3 (0.62) | SRD5A2ALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL5213552 | 0.85 | SLC7A5 (0.55) | FFAR1ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL1870609 | 0.85 | ALDH1A1 (0.62) | CYP4F2CYP4A11ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4675 | 0.85 | ALDH1A1 (0.62) | CYP4F2CYP4A11ALDH1A1HPGDSMN1; SMN2 | |
| Benzene SCHEMBL28096336 | 0.85 | ALDH1A1 (0.62) | CYP4F2CYP4A11ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7558146 | 0.84 | KMT2A (0.56) | CYP4F2CYP4A11EPHX2ALDH1A1MMP9 | |
| SCHEMBL6446114 | 0.84 | KMT2A (0.56) | CYP4F2CYP4A11EPHX2ALDH1A1MMP9 | |
| SCHEMBL5924358 | 0.84 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1MMP9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096420-B | Catalyst for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4041401-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-109096420-B | Catalyst for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-RE41135-E1 | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-7528282-B2 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBOTT LABORATORIES (US) | 2009-05-05 | — | — | US | disclosed |
| CN-101142172-A | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LAB (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| CN-1147481-C | Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases | - | 2004-04-28 | — | — | CN | disclosed |
| CN-1339028-A | Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases | HOFFMANN LA ROCHE (CH) | 2002-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | HSD17B1, HSD3B1, HSD17B2 | SRD5A2 13/4885CYP4F2 443/4885CYP4A11 101/4885 |
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | HCK, LYN, BTK | SRD5A2 3776/4885CYP4F2 1874/4885CYP4A11 1607/4885 |
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | SRD5A2 4036/4885CYP4F2 1729/4885CYP4A11 802/4885 |
| US-20060149070-A1 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid, for therapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | HSD17B1, HSD11B1, HSD3B1 | SRD5A2 17/4885CYP4F2 534/4885CYP4A11 68/4885 |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | SRD5A2 18/4885CYP4F2 286/4885CYP4A11 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.